In a report released today, Lawrence Keusch from Raymond James maintained a Buy rating on Zimmer Biomet Holdings (ZBH). The company’s shares closed last Friday at $138.52.
According to TipRanks.com, Keusch is a 4-star analyst with an average return of 4.4% and a 56.3% success rate. Keusch covers the Healthcare sector, focusing on stocks such as Baxter International, Intuitive Surgical, and Becton Dickinson.
Zimmer Biomet Holdings has an analyst consensus of Strong Buy, with a price target consensus of $158.67, implying a 13.5% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $160.00 price target.
See today’s analyst top recommended stocks >>
Based on Zimmer Biomet Holdings’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.23 billion and GAAP net loss of $207 million. In comparison, last year the company earned revenue of $1.99 billion and had a net profit of $134 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zimmer Biomet Holdings, Inc. provides musculoskeletal healthcare services. It designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities & trauma products, office based technologies, spine, craniomaxillofacial & thoracic products, dental implants and related surgical products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Zimmer Biomet Holdings was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
